human disease
6 statements, 0 sitelinks - 21:53, 5 March 2024
class of diseases that involve the heart or blood vessels
14 statements, 0 sitelinks - 16:45, 20 June 2023
rare form of cardiovascular disease
4 statements, 0 sitelinks - 20:41, 21 December 2023
cardiovascular system disease that primarily affects the blood vessels
5 statements, 0 sitelinks - 16:48, 20 June 2023
cardiovascular system disease that is located in the fibrous sac surrounding the heart
8 statements, 0 sitelinks - 23:15, 30 December 2023
disease characterized by plaque building up in the arteries of the heart
5 statements, 0 sitelinks - 10:38, 25 June 2023
cardiovascular system disease that involves the heart
7 statements, 0 sitelinks - 16:44, 20 June 2023
cardiovascular disease
16 statements, 0 sitelinks - 20:44, 21 December 2023
| complications = [[Cardiovascular disease/ja]], [[coronary artery disease/ja]]
...[[peripheral artery disease/ja|末梢動脈疾患]]を含む[[atherosclerotic cardiovascular disease/ja|動脈硬化性心血管系疾患]]（ASCVD）発症の危険因子である。脂質異常症はASCVDの危険因子であるが、異常値だからといって脂質低下薬を開始する
...
19 KB (475 words) - 20:46, 13 April 2024
...ク破裂]]、[[cardiovascular disease/ja|心血管疾患]]、[[stroke/ja|脳卒中]]、その他の[[vascular disease/ja|血管疾患]]のリスクを減少させることと関連している。HDL粒子は一般に「善玉コレステロール」と呼ばれるが、これは動脈壁から脂肪分子を運び出し、[
...ル（HDL-C）は、（LDL粒子内のコレステロールと同じであるにもかかわらず）「善玉コレステロール」と呼ばれることがある。HDL-Cの値が高い人は[[cardiovascular diseases/ja|心血管系疾患]]の問題が少ない傾向があるが、HDL-Cコレステロール値が低い人（特に40 mg/dL未満または約1 mmol/
...
23 KB (649 words) - 09:26, 10 March 2024
...国糖尿病学会]]の医療標準では、GLP-1作動薬は2型糖尿病の第一選択薬として、特に[[atherosclerotic cardiovascular disease/ja|動脈硬化性心血管病]]または[[obesity/ja|肥満]]を有する患者に推奨されている。
また、[[non-alcoholic fatty liver disease/ja|非アルコール性脂肪肝疾患]]、[[polycystic ovary syndrome/ja|多嚢胞性卵巣症候群]]、依存症などの[[reward
...
17 KB (521 words) - 16:46, 13 April 2024
| complications = [[Heart disease]], [[pancreatitis]]
| risks = [[Non-alcoholic fatty liver disease]], [[atherosclerosis]], [[alcoholism]], [[metabolic syndrome]]
...
8 KB (925 words) - 22:26, 15 April 2024
| complications = [[Heart disease]], [[pancreatitis]]
| risks = [[Non-alcoholic fatty liver disease]], [[atherosclerosis]], [[alcoholism]], [[metabolic syndrome]]
...
8 KB (969 words) - 22:24, 15 April 2024
...tes/ja]], [[hyperuricemia/ja]], [[obesity/ja]], [[nonalcoholic fatty liver disease/ja]], [[polycystic ovarian syndrome/ja]], [[erectile dysfunction/ja]], [[ac
メタボリックシンドロームは、[[cardiovascular disease/ja|心血管疾患]]や[[diabetes mellitus type 2/ja|2型糖尿病]]の発症リスクと関連している。米国では、成人人口の約25
...
29 KB (700 words) - 19:30, 28 February 2024
...saturated fat to promote health and reduce the risk from [[cardiovascular disease]]s.
===Cardiovascular disease===
...
14 KB (2,005 words) - 10:46, 10 May 2025
| complications = [[Heart disease/ja]], [[pancreatitis/ja]]
| risks = [[Non-alcoholic fatty liver disease/ja]], [[atherosclerosis/ja]], [[alcoholism/ja]], [[metabolic syndrome/ja]]
...
10 KB (363 words) - 22:41, 15 April 2024
==Types of disease==
** [[Graves-Basedow disease]]
...
7 KB (691 words) - 11:10, 16 February 2024
==Types of disease== <!--T:3-->
** [[Graves-Basedow disease]]
...
7 KB (737 words) - 13:22, 17 February 2024
| synonyms = Diabetic kidney disease
...l/分/1.73m<sup>2</sup>を超える正常値から15未満まで徐々に低下することがあり、その時点で患者は[[end-stage renal disease/ja|末期腎疾患]]であるといわれる。通常、何年もかけてゆっくりと進行する。
...
25 KB (667 words) - 16:27, 27 February 2024
| complications = [[Cardiovascular disease]], [[coronary artery disease]]
...d conditions and lifestyle in addition to dyslipidemia, is considered in a cardiovascular risk assessment. In developed countries, most dyslipidemias are [[hyperlipi
...
15 KB (2,054 words) - 17:52, 13 April 2024